XNCR News and Press, Xencor Inc. From 08/03/23

2023-08-03 16:32:45 ET Xencor press release ( NASDAQ: XNCR ): Q2 GAAP EPS of -$0.37 beats by $0.43 . Revenue of $45.5M (+50.8% Y/Y) beats by $19.22M . Cash, cash equivalents, receivables and marketable debt securities totaled $531.4 million as of June 30, 2023,...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2023 financial results after the market closes on Thursday, August 3, 2023. ...

2023-07-17 06:52:00 ET Summary Xencor is a leader in bispecific antibodies R&D. It has developed a number of approved molecules through big pharma partners. Its current pipeline is in the early to mid stage for the next phase in its lifecycle. Xencor ( XNCR )...

-- Engineered IL2-Fc Cytokine is Well-tolerated and Selectively Expands Regulatory T Cells -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today an...

2023-05-21 07:32:58 ET Summary Shares of antibody therapy concern Viridian Therapeutics, Inc. are off some 40% since setting an all-time high of $39.00 in January following a positive readout on lead candidate VRDN-001. Despite pivotal trial data not due until mid- and late 2024, ...

2023-05-08 22:25:19 ET Xencor, Inc. (XNCR) Q1 2023 Results Conference Call May 08, 2023 04:30 PM ET Company Participants Charles Liles - Head of Corporate Communications, Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief...

2023-05-08 16:48:41 ET Xencor press release ( NASDAQ: XNCR ): Q1 GAAP EPS of -$1.02 misses by $0.36 . Revenue of $18.96M (-77.8% Y/Y) misses by $7.93M . Based on current operating plans, Xencor expects to have cash to fund research and development programs and ...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after the market closes on Monday, May 8, 2023. Xenc...